Skip to main content

Understanding the Impact of Inhaled Corticosteroids on Adverse Events in People with Asthma

Asthma is a chronic condition that affects many millions of people worldwide, making it difficult for them to breathe due to inflamed airways. Inhaled corticosteroids (ICS) are a cornerstone of asthma treatment, significantly improving patients' quality of life by reducing symptoms, preventing asthma attacks, and improving lung function. However, while the benefits of ICS are well-established, there are concerns about potential adverse effects, particularly at higher doses.

The Role of Inhaled Corticosteroids

Inhaled corticosteroids are anti-inflammatory medications that are commonly prescribed to manage asthma. They work by reducing inflammation in the airways, making it easier to breathe and reducing the frequency of asthma exacerbations. According to current guidelines, patients should use the lowest effective dose of ICS to manage their asthma effectively.

Key Findings from Our Recent Research Study

Our recent study in the American Journal of Respiratory and Critical Care Medicine has shed light on the association between the dose of ICS and the frequency of adverse events. The study, which analysed data from two large UK nationwide databases, aimed to determine the risk of adverse effects from short-term ICS use in people with asthma. We found that:

Low-Dose ICS: Short-term use of low-dose ICS (≤200mcg per day) was not associated with significant adverse effects.

Medium-High Dose ICS: Use of medium (201-599mcg per day) and high doses (≥600mcg per day) of ICS was associated with an increased risk of several adverse outcomes, including major adverse cardiac events (MACE), arrhythmia, pulmonary embolism (PE), and pneumonia. The risk increased with higher doses.

Major Adverse Cardiac Events (MACE): We found that medium and high doses of ICS were associated with a significantly increased risk of MACE. For medium doses, the hazard ratio (HR) was 2.63, and for high doses, it was 4.63.

Arrhythmia: Similarly, the risk of arrhythmia was higher with medium doses (HR 2.21) and even more so with high doses (HR 2.91).

Pulmonary Embolism (PE): The risk of PE was also elevated, with hazard ratios of 2.10 for medium doses and 3.32 for high doses.

Pneumonia: We study found an increased risk of pneumonia at both medium (HR 2.25) and high doses (HR 4.09).

These findings highlight the importance of adhering to guideline recommendations to use the lowest effective ICS dose to manage asthma, thereby minimizing the risk of adverse events.

Implications for Asthma Management

Our study emphasises the need for clinicians to balance the benefits of ICS in controlling asthma with the potential risks associated with higher doses. Here are some key takeaways for both healthcare providers and patients:

Personalized Treatment Plans: Healthcare providers should tailor asthma treatment plans to each patient, ensuring that the ICS dose is sufficient to control symptoms while minimizing potential risks.

Regular Reviews: Regular asthma reviews and medication assessments should be conducted to ensure that patients are on the lowest effective dose of ICS. This includes considering step-down approaches when asthma is well-controlled.

Patient Education: Patients should be educated about the importance of adhering to their prescribed treatment and the potential risks of using higher doses of ICS without medical guidance.

Conclusion

Inhaled corticosteroids remain a vital component of asthma management, offering significant benefits in reducing symptoms and preventing exacerbations. However, this recent research underscores the importance of using the lowest effective dose to mitigate the risk of adverse events. By working closely with healthcare providers, patients can ensure that their asthma is managed effectively and safely. Finally, as we continue to learn more about the long-term effects of asthma medications, ongoing research and vigilance are crucial in optimizing treatment strategies for better health outcomes.


Comments

Post a Comment

Popular posts from this blog

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...
Post a Comment
Read more

UK Covid-19 Inquiry - The Importance of a Strong Primary Healthcare System

In my witness statement for Module 10 of the UK Covid-19 Inquiry, I discuss the pandemic's impact through from the perspectives of  primary care and public health, drawing on my extensive experience as a senior academic at Imperial College London and as a practising GP and NHS Public Health Specialist.  I emphasise that the pandemic disproportionately affected people who were clinically vulnerable, the disabled, ethnic minority communities and those living in deprived areas. The pandemic highlighted how structural inequalities, multigenerational housing, and employment in high-risk frontline roles exacerbated health disparities.  My statement also critiques the weakening of public health infrastructure - particularly for the control of infectious diseases - and the lack of integrated health data systems to identify at-risk groups such as the clinically vulnerable. I also advocated for a more robust preventive healthcare model that prioritises community-based primary care ...
Post a Comment
Read more

Relevance Over Recall: Rethinking How AI Uses Clinical Data

Our article in the Journal of the Royal Society of Medicine argues that safe and effective AI in healthcare must incorporate mechanisms that emulate human judgement - down-weighting old, inaccurate or superseded information and prioritising what is recent, clinically relevant and reaffirmed - so that AI supports, rather than disrupts, high-quality patient care.  Clinicians constantly revise, reinterpret and filter past information so that only what is relevant, accurate and timely shapes present-day management decisions; medical records function as dynamic “working tools” rather than fixed archives. By contrast, many AI systems lack this capacity for selective forgetting and often treat all historical data as equally meaningful.  This can lead to outdated or low-confidence diagnoses being repeatedly resurfaced, persistent labels influencing clinical expectations, and irrelevant, long-resolved events cluttering summaries and decision-support outputs. Such indiscriminate recall...
Post a Comment
Read more